[volver]
EML4-ALK rearrangement in blood platelets and outcome to crizotinib in non-small-cell lung cancer patients Karachaliou N, Nilsson J, Berenguer J, Gimenez Capitan A, Schellen P, Teixido C, Leonie Kuiper J, Drees E, Grabowska, van Keulen M, Tannous J, Heideman D, Thunnissen E, Dingemans A-M, Viteri Ramirez S, Tannous B, Drozdowskyj A, Smit E, Wurdinger T, Rosell R.
Abstract 8082. Poster
Association of non-disruptive P53 mutations with poor progression-free survival (PFS) in resected breast cancer treated with neoadjuvant chemotherapy Martinez-Bueno A, Baulies , Molina-Vila M.A, Bertran-Alamillo J, Gonzalez Cao M, Gonzalez X, Viteri Ramirez S, Karachaliou N, Teixido C, Sanchez-Ronco M, Tresserra F, Cusido M.T, Fabregas R, Rosell R.
Abstract, 1042. Poster
IDH 1 /2 status and low grade gliomas (LGG): Correlation with outcome upfront Pignatti criteria and molecular profile in a retrospective analysis of a single-centre cohort from Spain Etxaniz O, Carrato C, de Aguirre I, Queralt C, Munoz A, Ramirez J.L, Rosell R, Villà S, Diaz, R Estival A, Teixido P, Indacochea A, Ahlal S, Vilà Martinez L, Balana C.
Abstract 2046. Poster
The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials Lee C, Davies L, Wu Y-L, Mitsudomi T, Inoue A, Rosell R, Zhou C, Nakagawa K, Throngprasert S, Fukuoka M, Gralla R, Gebski V, Mok T, Chih-Hsin Yang J.
Abstract 8072. Poster
ROS1 rearrangement in non-small cell lung cancer (NSCLC): Prognostic and predicitve impact and genetic variability Scheffler M, Schultheis A, Teixido C, Yves S, Michels F, Morales-Espinosa D, Viteri S, Merkelbach-Bruse S, Fischer R, Fassunke J, Sebastian M, Heidi Serke M, Randerath W, Gerigk U, Ko Y-D, Krüger S, Schnell R, Rothe A, Rosell R, Büttner R, Wolf J.
Abstract 8066. Poster
Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non–small cell lung cancer (NSCLC) Camidge R, Bazhenova L, Salgia R, Langer C, Gold K, Rosell R, Tsang Shaw A, Weiss G, Narasimhan N, Dorer N, Rivera V, Clackson T, Conlan M, Kerstein D, Haluska F, Gettinger.
Abstract 8062. Poster
Validation of ERCC1 (E1) for response prediction to platinum-gemcitabine
Bepler G, Chen W, Patrick S, Astrow S, Stephens C, Gandara D, Rosell R, Ramirez J.L, Scagliotti G, Busso S, Volante M, Novello S.
Abstract 8036. Poster
Non-Small Cell Lung Cancer (NSCLC) harboring Epidermal Growth Factor Receptor mutations (EGFR-m) and breast cancer (BC): A retrospective analysis of a single institution. Moran T, Quiroga V, Carcereny Costa E, Cirauqui B, Margeli M, Vilà L, de los Llanos GIL Gil Moreno M, Indacochea A, Cuadra Urteaga J.L, Queralt C, de Aguirre I, Ramirez J.L, Castella E, Lopez Y, Mate J.L, Rosell R. Abstract e19112. Proceedings
Prevalence of ROS1 translocation, HER2, and BRAF mutations in a cohort of advanced Non-Small Cell Lung Cancer (NSCLC) patients (p) triple negative (TN)
Carcereny Costa E, Estival A, Vilà Martinez L, de los Llanos Gil Moreno M, Moran T, Gutierrez B, Nancy Perez E, Luis Y, Jove J, Buges C, Quiroga V, Cuadra-Urteaga J.L, Cros S, Hardy-Werbin M, Teruel I, Ahlal S, Pardo N, Indacochea A, Capdevila L, Rosell R.
Abstract e22139. Proceedings
BIM and SHP2 expression levels to predict clinical outcome to EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p). Garcia Campelo R, Moran T, Cardenal F, Alonso-Jaudenes Curbera G, Carcereny Costa E, Pallares E, Camps C, Insa A, Lopez-Vivanco G, Porta R, Bastus R, Isla D, Reguart N, Bover I, Majem M, Massuti B, Ramirez J.L, Drozdowskyj A, Karachaliou N, Rosell R.
Abstract e19078. Proceedings
Serial mutational analysis to monitor disease evolution in blood from advanced non small cell lung cancer (NSCLC) patients (p) Viteri Ramirez S, Mayo-de las Casas C, Jordana-Ariza N, Morales-Espinosa D, Molina-Vila M.A, Karachaliou N, Gonzalez Cao M, Simo-Perdigo M, Bertran-Alamillo J, Codony J, Garzon M, Perez-Rosado A, Martinez-Bueno A, Gonzalez X, Ovalle E, Rosell R.
Abstract e19085. Proceedings
DNA repair- and apoptosis-pathways to regulate response to chemo-radiotherapy (CRT) in patients (p) with locally advanced head and neck cancer (HNC) Cirauqui B, Quiroga V, Chaib I, Sanchez B, Karachaliou N, Ramirez J.L, Quer A, Munoz A, Drozdowskyj A, Pollan C, Planas I, Verges J, Cuadras P, Massuet A, Lezcano C, Vilà Martinez L, de los Llanos Gil M, Hardy M, Rosell R, Margeli M.
Abstract e17025. Proceedings
Analysis of gene expression in the re-replication pathway and selective blockade with checkpoint inhibitors as a potential therapeutic option in NSCLC Morales-Espinosa D, Molina-Vila M.A, Gimenez Capitan A, Garcia-Roman S, Bertran-Alamillo J, Mendez P, Ramirez-Serrano J.L, Codony C, Viteri Ramirez S, Karachaliou N, Rosell R.
Abstract e13516. Proceedings